A.P. Pharma, Inc. , a specialty pharmaceutical company, today announced that it has received a Complete Response Letter from the U.S. Food and Drug Administration regarding its New Drug Application for its lead product candidate, APF530, for the prevention of chemotherapy-induced nausea and vomiting .
http://www.drugs.com/nda/apf530_130329.html?
http://www.drugs.com/nda/apf530_130329.html?
No comments:
Post a Comment